Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women

Inclusion Criteria: * Documented positive test for HIV-1 infection * Subject is at least 18 and not older than 40 years of age at the day of the first dosing of study medication * Subject is able and willing to sign the Informed Consent Form prior to screening evaluations. * Pregnant for a maximum of 30 weeks at the day of first dosing of study medication Exclusion Criteria: * History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients, which may be employed in the trial. * Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. * Inability to understand the nature and extent of the trial and the procedures required. * Abnormal serum transaminases or creatinine, determined as levels being \> 3 times upper limit of normal. * Concomitant use of medications that interfere with Generic lopinavir/ritonavir pharmacokinetics * Active hepatobiliary or hepatic disease (N.B. chronic hepatitis B/C co-infection is allowed) * Documented previous virological failure of a lopinavir/ritonavir containing regimen or documented resistance to lopinavir/ritonavir prior to dosing